Yat Tip Tor

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of corns and calluses. It provides relief from pain associated with these conditions by effectively removing the corns and calluses.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application of the medicated plaster.

The affected area should be washed and dried thoroughly prior to application. A medicated plaster must then be applied directly over the corn or callus. After a duration of 48 hours, the medicated plaster should be removed. This procedure may be repeated every 48 hours as necessary, for a maximum duration of 14 days, or until the corn or callus is completely removed.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin is prohibited due to the potential for exacerbating the condition. Additionally, the product should not be applied to any area that is infected or reddened, as this may lead to further complications.

Patients with diabetes should avoid use, as the product may interfere with glycemic control or wound healing. Furthermore, individuals with poor blood circulation are advised against using this product, as it may pose a risk of inadequate tissue perfusion and subsequent adverse effects.

Warnings and Precautions

For external use only. This product contains natural rubber latex, which may cause allergic reactions in sensitive individuals. Healthcare professionals should be aware of this allergy alert when recommending this product to patients.

It is imperative to exercise caution when using this product. It should not be applied to irritated skin or any area that is infected or reddened. Additionally, individuals with diabetes or poor blood circulation should refrain from using this product due to potential complications.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients should be advised to discontinue use and consult a healthcare provider, such as a doctor or podiatrist, if discomfort persists. Furthermore, if any of the following symptoms occur—nausea, vomiting, abdominal discomfort, diarrhea, or skin rash—patients should stop using the product and seek medical advice promptly.

Side Effects

Patients should be aware of the potential for allergic reactions associated with this product, as it contains natural rubber latex. Such reactions may vary in severity and can be serious for individuals with latex allergies.

In clinical practice, patients are advised to discontinue use and consult a healthcare professional, such as a doctor or podiatrist, if they experience persistent discomfort. Additionally, the occurrence of nausea, vomiting, abdominal discomfort, diarrhea, or skin rash warrants immediate medical attention. These symptoms may indicate a need for further evaluation and management.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Yat Tip Tor (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients.

Due to the lack of data, it is advisable to closely monitor elderly patients for any potential adverse effects and to consider individual patient factors when determining the appropriateness of therapy.

Pregnancy

The safety of salicylic acid plaster during pregnancy has not been established, as the prescribing information does not provide specific data regarding its use in this population. Consequently, healthcare professionals should exercise caution when considering the use of salicylic acid plaster in pregnant patients. There are no available studies or risk categories to guide the assessment of potential fetal impacts or safety concerns associated with its use during pregnancy. Therefore, it is recommended that healthcare providers evaluate the necessity of treatment with salicylic acid plaster in pregnant patients on a case-by-case basis, weighing the potential benefits against any unknown risks.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, no data are provided concerning the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of information necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may arise from an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

Management of an overdose should be tailored to the specific substance involved and the clinical presentation of the patient. Supportive care is paramount, and interventions may include the administration of activated charcoal if the patient presents within a suitable timeframe and is not at risk for aspiration.

In severe cases, advanced medical interventions may be necessary, including but not limited to, intravenous fluids, vasopressors, or other symptomatic treatments as indicated. Consultation with a poison control center or a medical toxicologist is recommended for guidance on specific antidotes or additional management strategies.

It is crucial for healthcare professionals to document all findings and interventions thoroughly and to report any adverse events to the appropriate regulatory authorities as per local guidelines.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children and to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed.

Patients should be instructed not to use the medication on irritated skin or on any area that is infected or reddened. It is important to inform patients that the medication is contraindicated for individuals with diabetes or those who have poor blood circulation.

Healthcare providers should counsel patients to discontinue use and consult a doctor or podiatrist if discomfort persists. Additionally, patients should be made aware that they should stop using the medication and seek medical advice if they experience nausea, vomiting, abdominal discomfort, diarrhea, or a skin rash.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It should be stored at a temperature range of 15°C to 30°C (59°F to 86°F). Care should be taken to keep the product away from heat sources to maintain its integrity.

Additional Clinical Information

The medicated plaster is administered topically, applied directly over the corn or callus. After 48 hours, the plaster should be removed, and this procedure can be repeated every 48 hours as necessary for a maximum duration of 14 days, or until the corn or callus is effectively removed.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Yat Tip Tor, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)